Phaseline

Companies › Cinclus Pharma Holding

Cinclus Pharma Holding: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Gastroenterology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Linaprazan glurate
Potassium-competitive acid blocker (P-CAB); H+/K+-ATPase inhibitor
ATP4APhase 3GERD (Gastroesophageal Reflux Disease); PharmacokineticsNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07037875Linaprazan gluratePhase 3GERD (Gastroesophageal Reflux Disease)GastroenterologySep 2026
NCT05469854Linaprazan gluratePhase 1PharmacokineticsGastroenterologyNov 2026

Targets

ATP4A (1)

Companies with the same targets

Phathom Pharmaceuticals Il-Yang Pharm. Carnot Laboratories AstraZeneca

Companies built like this

Carnot Laboratories Phathom Pharmaceuticals Elgan Pharma Norgine Green Cross Wellbeing

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.